BioCentury
ARTICLE | Clinical News

Eidos' AG10 leads to >90% TTR stabilization at day 28 in Phase II

November 16, 2018 5:28 PM UTC

Eidos Therapeutics Inc. (NASDAQ:EIDX) said AG10 led to >90% stabilization of transthyretin (TTR) at day 28 in all treated patients in a Phase II trial to treat symptomatic TTR amyloid cardiomyopathy. Twice-daily AG10 significantly increased serum TTR concentrations at day 28 by 36% at the 400 mg dose and by 50% at the 800 mg dose vs. a decrease of 7% for placebo (p<0.0001 for both). AG10 was well tolerated. Data were presented at the American Heart Association (AHA) meeting in Chicago.

The double-blind, U.S. trial enrolled 49 patients with symptomatic wild-type or mutant TTR amyloid cardiomyopathy...

BCIQ Company Profiles

Eidos Therapeutics Inc.

BCIQ Target Profiles

Transthyretin (TTR)